ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

The stock's fall snapped a two-day winning streak.

I think AbbVie is a fantastic stock to buy for income investors who also like some growth. The company is a Dividend King, ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Pharmaceutical stock AbbVie (ABBV) reported fourth-quarter results that handily beat analyst expectations on the top and bottom line. ABBV stock is up 7% in morning trading on the strength of its ...

The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development, over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...